Literature DB >> 15274338

CD44s expression, in benign, borderline and malignant tumors of ovarian surface epithelium. Correlation with p53, steroid receptor status, proliferative indices (PCNA, MIB1) and survival.

N Zagorianakou1, D Stefanou, G Makrydimas, P Zagorianakou, E Briasoulis, B Karavasilis, N J Agnantis.   

Abstract

AIM: To investigate the role of CD44s in the biological behavior of surface epithelial ovarian tumors and its correlation with clinicopathological parameters, prognosis, p53, steroid receptor status and proliferative indices (PCNA, MIB1).
MATERIALS AND METHODS: We analyzed a total of 83 patients with ovarian surface epithelial tumors, for the immunohistochemical expression of CD44s and the possible correlation with clinicopathological factors and patients' outcome.
RESULTS: A statistically significant correlation was found between the expression of CD44s, which was higher in cancer cases than in benign cystadenomas (p<0.0001) and, between cancer cases, which was lower in borderline tumors, (p=0.05). No statistical correlation was found between CD44s expression and the examined markers. In overall survival analysis we did not detect a statistically significant correlation with the expression of CD44s.
CONCLUSION: The current study demonstrates that CD44s may be functionally involved in the pathogenesis of epithelial ovarian lesions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15274338

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  CD44s is useful in the differentiation of benign and malignant papillary lesions of the breast.

Authors:  G M K Tse; P-H Tan; T K F Ma; C B Gilks; C S P Poon; B K B Law
Journal:  J Clin Pathol       Date:  2005-11       Impact factor: 3.411

2.  Intraperitoneal delivery of platinum with in-situ crosslinkable hyaluronic acid gel for local therapy of ovarian cancer.

Authors:  Eun Jung Cho; Bo Sun; Kyung-Oh Doh; Erin M Wilson; Sandra Torregrosa-Allen; Bennett D Elzey; Yoon Yeo
Journal:  Biomaterials       Date:  2014-10-24       Impact factor: 12.479

3.  CD44 standard form expression is correlated with high-grade and advanced-stage ovarian carcinoma but not prognosis.

Authors:  Jing Zhang; Bin Chang; Jinsong Liu
Journal:  Hum Pathol       Date:  2013-05-07       Impact factor: 3.466

4.  Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.

Authors:  Alaa A Elzarkaa; Bassma El Sabaa; Doaa Abdelkhalik; Hassan Mansour; Mahmoud Melis; Waleed Shaalan; Mohamed Farouk; Eduard Malik; Amr A Soliman
Journal:  J Cancer Res Clin Oncol       Date:  2016-01-13       Impact factor: 4.553

5.  A Study of CD44 Positive Cancer Cells in Epithelial Ovarian Cancer and their Correlation with P53 And Ki67.

Authors:  Ketaki Kar; Suman Ghosh; Anup Kumar Roy
Journal:  J Lab Physicians       Date:  2021-02-22

Review 6.  Role of versican, hyaluronan and CD44 in ovarian cancer metastasis.

Authors:  Miranda P Ween; Martin K Oehler; Carmela Ricciardelli
Journal:  Int J Mol Sci       Date:  2011-01-31       Impact factor: 5.923

7.  Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer.

Authors:  Yan Gao; Rosemary Foster; Xiaoqian Yang; Yong Feng; Jacson K Shen; Henry J Mankin; Francis J Hornicek; Mansoor M Amiji; Zhenfeng Duan
Journal:  Oncotarget       Date:  2015-04-20

Review 8.  Expression and Function of CD44 in Epithelial Ovarian Carcinoma.

Authors:  Joelle D Sacks; Maria V Barbolina
Journal:  Biomolecules       Date:  2015-11-11

9.  5-Year Survival in Gastric Adenocarcinoma with Epithelial and Stromal Versican Expression.

Authors:  Mohammad Hossein Sanei; Omid Mirmosayyeb; Ali Chehrei; Jamshid Ansari; Elahe Saberi
Journal:  Iran J Pathol       Date:  2018-12-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.